Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

NCT00984126 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Haemophilia A

Interventions

DRUG: turoctocog alfa
DRUG: turoctocog alfa

Sponsor

Novo Nordisk A/S